Comorbidities increase in-hospital mortality in dengue patients in Brazil

Dengue remains an unmet public health burden. We determined risk factors for dengue in-hospital mortality in Brazil. Of 326,380 hospitalised dengue cases in 9-45-year-old individuals, there were 971 deaths. Risk of dying was 11-times higher in the presence of underlying common comorbidities (renal,...

Full description

Saved in:

Bibliographic Details
Published in:	Memórias do Instituto Oswaldo Cruz Vol. 113; no. 8; p. e180082
Main Authors:	Werneck, Guilherme L, Macias, Alejandro E, Mascarenas, Cesar, Coudeville, Laurent, Morley, David, Recamier, Vincent, Guergova-Kuras, Mariana, Puentes-Rosas, Esteban, Baurin, Nicolas, Toh, Myew-Ling
Format:	Journal Article
Language:	English
Published:	Brazil Instituto Oswaldo Cruz, Ministério da Saúde 23-07-2018 Fundação Oswaldo Cruz (FIOCRUZ)
Subjects:	Adolescent Adult Brazil - epidemiology case fatality rate Child Comorbidity dengue Dengue - epidemiology Dengue - mortality Female haemorrhagic fever Hospital Mortality Humans Kidney Diseases - mortality Latin America Male Middle Aged PARASITOLOGY Prevalence Retrospective Studies Risk Factors Severe Dengue - diagnosis Severe Dengue - mortality Short Communication Survival Analysis TROPICAL MEDICINE Young Adult haemorrhagic fever dengue case fatality rate Latin America
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Dengue remains an unmet public health burden. We determined risk factors for dengue in-hospital mortality in Brazil. Of 326,380 hospitalised dengue cases in 9-45-year-old individuals, there were 971 deaths. Risk of dying was 11-times higher in the presence of underlying common comorbidities (renal, infectious, pulmonary disease and diabetes), similar to the risk of dying from severe dengue and much higher with the combination. Ensuring access to integrated dengue preventative measures in individuals aged ≥ 9 years including those with comorbidities may help achieve the WHO objective of 50% reduction in mortality and 25% reduction in morbidity due to dengue by 2020.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 AUTHORS’ CONTRIBUTION All authors were involved in the concept and design of the study. All authors contributed to the interpretation of the data and participated in the preparation of this manuscript, and approved the final manuscript for submission. All authors had access to the study data and are responsible for the veracity and completeness of the data reported. Conflict of interest: AEM has no conflicts of interest. GW was partially funded by Sanofi Pasteur; CM, LC, EP-R, NB and M-LT are employees of Sanofi Pasteur; DM, VR and MG-K are employees of Ariana Pharmaceuticals who were contracted to undertake the analysis.
ISSN:	0074-0276 1678-8060 1678-8060
DOI:	10.1590/0074-02760180082